Search is Powered by Google
Cancer / Oncology News

IU Simon Cancer Center Director Honored By Indiana Governor

Main Category: Cancer / Oncology
Also Included In: Medical Students / Training
Article Date: 14 Jan 2009 - 2:00 PST

email icon email to a friend   printer icon printer friendly   write icon view / write opinions   rate icon rate article


Current Article Ratings:

Patient / Public:5 stars

5 (1 votes)

Health Professional:not yet rated

Article Opinions: 0 posts

Stephen Williams, M.D., the founding director of the Indiana University Melvin and Bren Simon Cancer Center , has been honored with a Sagamore of the Wabash, the highest honor an Indiana governor can bestow. Dr. Williams, who is stepping down from the role he has held since the cancer center was formed in 1992, was formally recognized Jan. 12 for his distinguished service to the state. Mitch Roob, Indiana secretary of commerce and CEO of the Indiana Economic Development Corp., presented the award to Dr. Williams during a reception attended by family, friends and colleagues.

"Dr. Williams has truly made an impact that goes beyond the borders of our state," said D. Craig Brater, M.D., dean of the IU School of Medicine. "Thanks to his leadership, Dr. Williams has built a cancer center that has evolved into one recognized by our country's premiere cancer agency, the National Cancer Institute.

"Hoosiers from all of Indiana's 92 counties have sought treatment there as have others from all 50 states and many countries. They seek treatment at the IU Simon Cancer Center because its researchers have developed the standard of care for many cancers and because its physicians - like Dr. Williams himself - are dedicated and compassionate individuals. We are indebted to Dr. Williams because he has been a driving force in changing cancer care in Indiana."

The IU Simon Cancer Center was first recognized in 1999 with an NCI designation, which was renewed in 2004 and 2008. The center remains Indiana's only NCI-designated center that provides patient care and one of only 64 in the nation.

Dr. Williams, the H.H. Gregg Professor of Oncology at the IU School of Medicine, is a clinical researcher with national recognition for his expertise in the use of cisplatinum in the treatment of ovarian cancer. He is recognized in America's Top Doctors for Cancer, and during his tenure, the cancer center has consistently ranked among the top clinical programs in the country, according to U.S. News & World Report.

A native Hoosier, Dr. Williams graduated from the IU School of Medicine in 1971 and completed his residency and oncology fellowship at IU. He was the first oncologist appointed at the Roudebush Veterans Administration Medical Center in Indianapolis in 1978 and only the second medical oncologist to serve on the Indiana University School of Medicine faculty. He was named associate dean for cancer research at the IU School of Medicine in 2007.

Indiana University Melvin and Bren Simon Cancer Center




Personalized Homepage Weekly Newsletters Daily News Alerts
Opioid Induced Constipation ADHD Anxiety Asthma Autism Cancer Diabetes Lung Cancer Lupus Medicare / Medicaid Obesity and BMI Pancreatic Cancer Stem Cells All 'What Is...' Articles All 'How To...' Articles

Ophthalmology Urology
About Us News Licensing Free Website Feeds Free Tools & Content Tell a Friend Accessibility Help / FAQ Article Submission Links Contact Us

add medical news today to your facebook
medical news gadget

Swine Flu Image

Swine Flu Updates

- Latest Swine Flu News
- What is Swine Flu?
- Map Of H1N1 Outbreaks
- Swine Flu - Top 20 FAQ
- Daily Email News Alerts
Stick with Medical News Today for the latest news updates on swine flu.


These are the most read articles from this news category for the last 6 months:
Top Article Star
Understanding And Treating Triple-Negative Breast Cancer
07 Jan 2009
Triple-negative breast cancer is a subtype of breast cancer that is clinically negative for expression of estrogen and progesterone receptors (ER/PR) and HER2 protein. It is characterized by its unique molecular profile...


Monitoring and Adherence in CML image Monitoring and Adherence in CML

Imatinib, or Gleevec, is a targeted anti-cancer drug that can keep chronic myelogenous leukemia (CML) in check for most patients for many years. It is important for patients to take imatinib as prescribed by their doctor to fight the disease and to guard against resistance...

Treating HER2+ Breast Cancer image Treating HER2+ Breast Cancer

There are at least four different kinds of breast cancer and each is treated differently. For HER2+ breast cancer, a chemotherapy drug is typically the best option. Here's an overview of the drugs used to treat breast cancer...

View more videos...